High prevalence of fatty acid synthase expression in colorectal cancers in middle eastern patients and its potential role as a therapeutic target

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1790-1801

  Uddin, Shahab ^a   Hussain, Azhar R ^a   Ahmed, Maqbool ^a   Abubaker, Jehad ^a   Al Sanea, Nasser ^a   Abduljabbar, Alaa ^a   Ashari, Luai H ^a   Alhomoud, Samar ^a   Al Dayel, Fouad ^a   Bavi, Prashant ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER; C 75; CASPASE 3; CYTOCHROME C; DNA; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG DOSE COMPARISON; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MIDDLE EAST; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOPSY, NEEDLE; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FATTY ACID SYNTHETASE COMPLEX; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MICE; MICE, NUDE; MICROSATELLITE INSTABILITY; MIDDLE EAST; MULTIVARIATE ANALYSIS; PARAFFIN EMBEDDING; PROBABILITY; PROPORTIONAL HAZARDS MODELS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650438905     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.230     Document Type: Article

References (42)

1. Watanabe T, Kobunai T, Toda E et al. Distal colorectal cancers with micro-satellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res 2006; 66: 9804-8.
2. Abubaker J Bavi P , Al-Harbi S et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008; 27: 3539-45.
3. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041-7.
4. Khamly K, Jeford M, Michael M et al. Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opin Investig Drugs 2005; 14: 607-28.
5. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-8.
6. Semenkovich CF. Regulation of fatty acid synthase (FASN). Prog Lipid Res 1997;36:43-53.
7. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-80.
8. Rossi S, Graner E, Febbo P et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003;1:707-15.
9. Alo' PL, Visca P, Marci A et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996;77:474-82.
10. Gansler TS, Hardman W III, Hunt DA et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28:686-92.
11. Ogino S, Kawasaki T, Ogawa A et al. Fatty acid synthase over-expression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol 2007; 38: 842-9.
12. Wang YY, Kuhajda FP, Cheng P et al. A new model ELISA, based on two monoclonal antibodies, for quantification of fatty acid synthase. J Immu-noassay Immunochem 2002;23:279-92.
13. Pizer ES, Pflug BR, Bova GS et al. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 2001;47:102-10.
14. Pizer ES, Thupari J, Han WF et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000;60:213-8.
15. De chrijver E, Brusselmans K, Heyns W et al. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003; 63: 3799-804.
16. Pizer ES, Wood FD, Heine HS et al. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996;56:1189-93.
17. Bandyopadhyay S, Pai SK, Watabe M et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor syn-ergizes with FAS siRNA to induce apoptosis. Oncogene 2005; 24: 5389-95.
18. Porstmann T, Griffths B, Chung YL et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005; 24: 6465-81.
19. Yang YA, Han WF, Morin PJ et al. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 2002; 279: 80-90.
20. Wang HQ, Altomare DA, Skele KL et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005; 24: 3574-82.
21. Franke TF, Hornik CP, Segev L et al. PI3K/Akt and apoptosis: size matters. Oncogene 2003; 22: 8983-98.
22. Nicholson KM, Anderson NG The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-95.
23. Reichert M, Saur D, Hamacher R et al. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007;67:4149-56.
24. Häusler P , PapofG, Eramo Aet al. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur J Immunol 1998;1:57-69.
25. Di Cristofano A, Kotsi P, Peng YF et al. Impaired Fas response and autoim-munity in Pten+/ - mice. Science 1999; 285: 2122-5.
26. Bavi P , Jehan Z, Atizado V et al. Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1708-18.
27. Siraj AK, Bavi P, Abubaker JA et al. Genome-Wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-met as a novel target for cancer therapy. J Pathol 2007; 213: 190-9.
28. Uddin S, Hussain AR, Siraj AK et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-86.
29. Shapira M, Ben-Izhak O, Bishara B et al. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer 2004;8:1615-21.
30. Hussain AR, Al-Rasheed M, Manogaran P et al. Curcumin induces apoptosis via inhibition of PI3 ' -kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006;11:245-54.
31. Hussain AR, Al-Jomah NA, Siraj AK et al. Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007; 67: 3888-97.
32. Uddin S, Hussain A, Al-Hussein K et al. Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004; 320: 932-8.
33. Uddin S, Hussain AR, Al-Hussein KA et al. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005; 11: 3102-8.
34. Uddin S, Hussain AR, Manogaran PS et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005; 24: 7022-30.
35. Bazzaro M, Lee MK, Zoso A et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006; 66: 3754-63.
36. Milgraum LZ, Witters LA, Pasternack GR et al. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997; 3: 2115-20.
37. Knowles LM, Axelrod F, Browne CD et al. fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 2004; 279: 30540-5.
38. McCarthy AD, Hardie DG Fatty acid synthase: an example of protein evolution by gene fusion. Trends Biochem Sci 1984960-3.
39. Cho KR, Vogelstein B. Genetic alterations in the adenoma - carcinoma sequence. Cancer 1992;70:1727-31.
40. Hamilton SR. The molecular genetics of colorectal neoplasia. Gastroenter-ology 1993;105:3-7.
41. Nishisho I, Nakamura Y, Miyoshi Y et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253: 665-9.
42. Gabrielson EW, Pinn ML, Testa JR et al. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 2001; 7: 153-7.